Aliment Pharmacol Ther 1993; 7: 691–698.

Index

24-hour pH-monitoring, 509
2, 4-dinitrofluorobenzene, 201
5-amino salicylates, 567
5HT$_3$-antagonist, 543
6-mercaptopurine/azathioprine, 117
^{99m}Tc labelled-sulcrafate, 531
acetaminophen, 477
acid, 589
acid inhibition, 191
acid secretion, 417, 537
acid suppression, 629
acid-peptic disease, 597
agonist, 267
Ainley, C. C. *see* Greenfield, S. M.
Alexander-Williams, J. *see* Tovey, F. I.
alginate, 385
alpha interferon, 331
amoxycillin, 111, 149, 313
analogue, 323
Angerson, W. *see* Taha, A. S.
angiogenesis, 581
Anic, B. *see* Banic, M.
Annibale, B. *see* Corleto, V.
antagonist, 267, 267, 267
Anthony, A., Dhillon, A. P., Nygard, G., Hudson, M., Piasecki, C., Strong, P., Trevethick, M. A., Clayton, N. M., Jordan, C. C., Pounder, R. E. & Wakefield, A. J., Early histological features of small intestinal injury induced by indomethacin, 29
Anthopoulou, H. *see* Arvanitakis, C.
anti-reflux agents, 553
antimicrobial therapy, 111
antimuscarinergic agent, 75
Arisawa, T. *see* Tsukamoto, Y.
Armstrong, D. *see* Duroux, P.
arthritis, 41, 197
Arvanitakis, C., Nikopolous, A., Theoharidis, A., Giannoulis, E., Vagios, I., Anthopoulou, H., Michailidis, D., Toukantonis, A., Cisapride and ranitidine in the treatment of gastro-oesophageal reflux—a comparative randomized double-blind trial, 635
aspirin, 575
Atkinson, M. *see* Robertson, C. S.
Axon, A. T. R. *see* Lobo, A. J.

Baak, L. C. *see* Janssen, M.
BALB-c mice, 201
Balks, H. J. *see* Dammann, H. G.
Ballinger, A. B. *see* Catnach, S. M.
Banic, M., Brkic, T., Anic, B., Rotkvic, I., Grabarevic, Z., Duvnjak, M., Troskot, B. & Mihatov, S., Effect of methylprednisolone on small bowel, spleen and liver changes in a murine model of inflammatory bowel disease, 201
Barbara, L. *see* Vaira, D.
Baron, J. H. *see* Logan, R. P. H.
Barrett's disease, 623
Barthel, J. S. *see* Marshall, J. B.
Bassendine, M. F. *see* Mitchison, H. C.
Battaglia, G., Di Mario, F., Vigneri, S., Dal Santo, P., Pilotto, A., Mazzacca, G., GISU, Peptic ulcer in the elderly—a double-blind short-term study comparing nizatidine 300 mg with ranitidine 300 g, 643
Bauerfein, P. *see* Duroux, P.
Beattie, S. *see* Collins, R.
Beattie, S. *see* McCarthy, C. J.
beclamethasone dipropionate, 125
Becx, M. C. J. M. *see* Witteman, E. M.
Beekman, H. *see* Taha, A. S.
Belloli, C. *see* Brignola, C.
Benya, R. V. *see* Metz, D. C.
beta-adrenoreceptor, 267
betamethasone, 125
bethanechol, 5
Bianchi Porro, G. *see* Lazzaroni, M.
bile acid therapy, 617
bile acids, 629
Bilic, A. *see* Ljubicic, W.
biofeedback, 487
Biollaz, J. *see* Duroux, P.
biotransformation, 477
bismuth citrate, 575
bismuth subsalicylate, 111
Bjorkman, D. J. *see* Schembre, D.
Bliesath, H. *see* Hartmann, M.
blood flow, 41
Blum, A.-L. *see* Duroux, P.
bolus injections, 455
Boyd, E. J. S. *see* Penston, J. G.
Brenna, E. *see* Waldum, H. L.
Brignola, C., Belloli, C., De Dimone, G., Evangelisti, A., Parente, R., Mancini, R., Mocheggiani, E., Fabris, N., Morini, M. C. & Licastro, F., Zinc supplementation restores plasma concentrations of zinc and thylium in patients with Crohn's disease, 275
Brkic, T. *see* Banic, M.
Brook, M. G., Main, J., Yap, I., Chan, G., Karayiannis, P., Crossey, M. & Thomas, H. C., Short report: prednisolone withdrawal followed by lympoblastoid interferon in the therapy of adult patients with presumed childhood-acquired hepatitis B virus infection, 333
Brunetti, G. *see* Vaira, D.
budesonide, 125, 611
budesonide enema, 401

Burke, D. A. *see* Lobo, A. J.
Burnham, W. R. *see* McIntyre, A. S.
Burroughs, A. K. *see* Osman, E.

calcium polycarbophil, 87
Camilleri, M. *see* Valdovinos, M. A.
Campbell, C. J. *see* Stables, R.
carcinoid mediators, 61
Carpani de Kaski, M. & Hodgson, H. J. F., Rolling review: inflammatory bowel disease, 567
Cassetta, M. R. *see* Corleto, V.
Catnach, S. M., Ballinger, A. B., Law, P. A., Nellans, H. & Fairclough, P. D., Dose-dependent stimulation of gallbladder contraction by intravenous erythromycin in man, 55
Chan, G. *see* Brook, M. G.
chemotherapy, 467
chenodeoxycholic acid, 139
children, 523
cholestasis, 21
chymotrypin, 629
cimetidine, 81, 429, 581, 553
ciprofloxacin, 149
cirrhosis, 233
cisapride, 5, 409, 617, 635
cisapride therapy, 181
Clayton, N. M. *see* Anthony, A.
Clayton, N. M. *see* Stables, R.
clinical study, 611
clinical trial, 111
Clitherow, J. W. *see* Stables, R.
colitis, 357
Collins, C. E. *see* Rampton, D. S.
Collins, R. *see* McCarthy, C. J.
Collins, R., Beattie, S., Xia, H. X. & O'Morain, C., Short report: high-dose omeprazole and amoxycillin in the treatment of *Helicobacter pylori*-associated duodenal ulcer, 315
Colombo, P. *see* Vaira, D.
colonoscopy, 655
combination treatment, 581
Connery, K. L. *see* Toskes, P. P.
constipation, 487
continuous infusion, 455
contraction, 29
Corbelli, C. *see* Vaira, D.
Corleto, V., Annibale, B., D'Ambra, G., Saggioro, A., Ferrua, B., Cassetta, M. R. & Delle Fave, G., Efficacy of long-term therapy with low doses of omeprazole in the control of gastric acid secretion in Zollinger–Ellison syndrome patients, 167
corticosteroids, 125, 567
Crohn's disease, 117, 275, 357, 567, 611
Crombie, D. L. *see* Mcquaid, K. R.
Crombie, I. K. *see* Penston, J. G.
Crossey, M. *see* Brook, M. G.
Crowe, J. P., Hepworth-Jones, B. & Taylor, M. D. & Richardson, P. D. I., Does 40 mg omeprazole daily offer additional benefit over 20 mg daily in patients requiring more than 4 weeks of treatment for symptomatic reflux oesophagitis?, 501
cyclosporin, 117
cytochrome P450, 477
cytoprotection, 575

Dal Santo, P. *see* Battaglia, G.
Damaschke, A. *see* Dammann, H. G.
D'Ambra, G. *see* Corleto, V.
Damgaard Pederson, N.-E. *see* Johnsson, F. Dammann, H. G., Von Zur Muhlen, A., Balks, H. J., Damaschke, A., Hennig, U., Schwarz, J. A. & Fuchs, W., The effects of lansoprazole, 30 or 60 mg daily, on intragastric pH and on endocrine function in healthy volunteers, 191
Danielsson, A., Edsbacker, S., Löfberg, R., Nilsson, A., Nyman-Pantelidis, M., Olsson, O., Suhr, O. & Willen, R., Pharmaco-kinetics of budesonide enema in patients with distal ulcerative colitis or proctitis, 401
Dasarathy, S. *see* Misra, S. C.
De Dimone, G. *see* Brignola, C.
De Koning, R. W. *see* Witteman, E. M.
Decktor, D. L. *see* Robinson, M.
Defilippi, C. & Gomez, E., Short report: effect of two prokinetic drugs on the electrical and motor activity of the small bowel in dogs, 329
Delchier, J. C. *see* Vidon, N.
Delle Fave, G. *see* Corleto, V.
Desideri, S. *see* Lazzaroni, M.
Dhillon, A. P. *see* Anthony, A.
Di Mario, F. *see* Battaglia, G.
diclofenac, 197
Dijkmans, B. A. C. *see* Janssen, M.
Ditschuneit, H. *see* Malfertheiner, P.
Dixon, J. S. *see* Penston, J. G.
Dohmann, R. *see* Frieling, T.
domperidone, 5, 327
Doppler, 41
double-blind, 443
double-blind study, 191
drug absorption, 317
drug-induced hypochlorhydria, 317
duodenal ulcer, 111, 233, 259, 313, 443, 463
duodenum H. pylori, 41
Duroux, P., Emde, C., Bauerfeind, P., Biollaz, J., Armstrong, D. & Blum, A.-L., Early evening nizatidine intake with a meal optimizes the antisecretory effect, 47
Dutreuil, C. *see* Vidon, N.
Duvnjak, M. *see* Banic, M.
dyspepsia, 457, 531

Edsbacker, S. *see* Danielsson, A.
eicosanoids, 357
elderly, 643
Elitsur, Y. *see* Lin, C.-H.
Emde, C. *see* Duroux, P.
Enck, P. *see* Frieling, T.
endoscopic healing, 409

enema, 561
enterochromaffin like cell (ECC), 589
enteropancreatic, 247
enteropathy, 197
eradication, 149
erosive oesophagitis, 67
erythromycin, 5, 55
ESWL, 617
ethanol, 131
Euler, A. E. *see* Mcquaid, K. R.
Evangelisti, A. *see* Brignola, C.
Evans, D. F. *see* Robertson, C. S.
evening primrose oil, 159
experimentally induced, 201
Eyre-Brook I. A. *see* Gore, S.

Faber Vestergaard, B. *see* Jarløv, A. E.
Fabris, N. *see* Brignola, C.
faecal impaction, 523
Fairclough, P. D. *see* Catnach, S. M.
famotidine, 167, 317, 443
fasting gallbladder volume, 617
Fehervari, I. *see* Tulassey, Z.
Feigenbaum, K. M. *see* Metz, D. C.
Fennerty, M. B., Sampliner, E. & Garewal, H. S., Review article: Barrett's oesophagus—cancer risk, biology and therapeutic management, 339
Ferrua, B. *see* Corleto, V.
first-pass metabolism, 131
fish oil, 159
Fishbeyn, V. A. *see* Metz, D. C.
fistula, 323
Flautner, L. *see* Tulassey, Z.
fluconazole, 317
fluticasone propionate, 125
food interaction, 47
French Co-operative Study Group *see* Poynard, T. Frieling, T., Enck, P., Dohmann, R., Wienbeck, M. & Luebke, H. J., The effect of trospium chloride on oesophageal motility, 75
Fuchs, W. *see* Dammann, H. G.
fulminant hepatic failure, 477

gallbladder contraction, 55
gallbladder mobility, 617
gallstone, 139
gallstones, 617
Garewal, H. S. *see* Febberty, M. B.
gastin, 589
gastric acid, 247, 597
gastric acid secretion, 167
gastric acidity determination, 455
gastric emptying, 457, 553, 629
gastric injury, 575
gastric pH, 537
gastric retention, 531
gastric surgery, 429
gastric ulcer, 111, 581
gastrin, 393
gastrinoma, 467, 597
gastro-oesophageal reflux, 181, 553, 501
gastro-oesophageal reflux disease, 81, 635
gastrointestinal symptoms, 457
Gattuso, J. M. & Kamm, M. A. Review article: the management of constipation in adults, 487
Gear, M. W. L. *see* Gore, S.
Geldof, H., Hazelhoff, B. & Otten, M. H., Two different dose regimens of cisapride with the treatment of reflux oesophagitis: a double-blind comparison with ranitidine, 409
Genta, R. M. *see* Graham, D. Y.
GERD, 5
Geus, W. P., Vinks, A. A. T. M., Smith, S. J., Westra, P. & Lamers, C. B. H. W., Comparison of two intravenous ranitidine regimens in a homogenous population of intensive care unit patients, 451
Giannoulis, E. *see* Arvanitakis, C.
GISU *see* Battaglia, G.
Glasbrenner, B. *see* Malfertheiner, P.
glucocorticosteroids, 611
Gomez, E. *see* Defilippi, C.
Gore, S., Healey, C. J., Sutton, R., Eyre-Brook, I. A., Gear, M. W. L., Shepherd, N. A., Wilkinson, S. P., Regression of columnar lined (Barrett's) oesophagus with continuous omeprazole therapy, 623
Goto, H. *see* Tsukamoto, Y.
Grabarevic, Z. *see* Banic, M.
Graham, D. Y., Lew, G. M., Ramirez, F. C., Genta, R. M., Klein, P. D. & Malaty, H. M., Short report: a non-metronidazole triple therapy for eradication of *Helicobacter pylori* infection—tetracycline, amoxycillin, bismuth, 111
granisetron, 5, 175
Green, A. T. *see* Greenfield, S. M.
Greenfield, S. M., Green, A. T., Teare, J. P., Jenkins, A. P., Punchard, N. A., Ainley, C. C. & Thompson, R. P. H., A randomized controlled study of evening primrose oil and fish oil in ulcerative colitis, 159
Greenfield, S. M., Punchard, N. A., Teare, J. P. & Thompson, R. P. H., Review article: the mode of action of the aminosalicylates in inflammatory bowel disease, 369
Griffioen, G. *see* Van De Wal, Y.
Grinham, R. *see* Stables, R.
Gummett, P. A. *see* Logan, R. P. H.

H_2-antagonists, 467, 553, 575
H_2-receptor antagonists, 81, 131, 417, 429
haemorrhage, 429
Hamilton, H. *see* McCarthy, C. J., Hammer, J., Philips, S. F., Talley, N. J. & Robertson, C., An investigation into the effect of cimetidine pre-treatment on raft formation of an anti-reflux agent, 553
Hartmann, M., Bliesath, H., Luhmann, R., Wurst, W., Letter to the Editors, 115
Hase, S. *see* Tsukamoto, Y.
Hawkey, C. J. *see* Hydson, N.
Hawkey, C. J. *see* Turnbull, G. M.

Hazelhoff, B. *see* Geldof, H.
Healey, C. J. *see* Gore, S.
healthy volunteers, 191
heartburn, 67, 501
Heitz, W. *see* Ziegenhagen, D. J.
Helicobacter pylori, 111, 313, 443, 463, 683
Hennig, U. *see* Dammann, H. G.
hepatic necrosis, 477
hepatitis B, 331
hepatoxicity, 477
Hepworth-Jones, B. *see* Crowe, J. P.
histamine, 589
histamine H_2-receptor antagonists, 247
Hogan, D. L. *see* Koss, M. A.
Holmfield, J. H. M. *see* Primrose, J. N.
Hopman, W. P. F. *see* Witteman, E. M.
hospital admissions, 429
Hudson, M. *see* Anthony, A.
Hudson, M. *see* Lim, S. G.
Hudson, N., Wilkinson, M. J., Swannell, A. J., Steele, R. J. & Hawkey, C. J., Ileo-caecal ulceration associated with the use of diclofenac slow release, 197
human, 417
Hunter, S. *see* Mcquaid, K. R.
hydrocortisone, 125
hypersecretion, 467
hypo/anacidity, 589
hypochlorhydria, 317

Iishi, H. *see* Tatsuta, M.
ileo-caecal ulceration, 197
immunoglobulin G, 561
immunosuppressive drugs, 117
immunosuppressives, 567
indomethacin, 29, 293
inflammation, 29
inflammatory bowel disease, 117, 201, 281, 369, 655
intensive care patients, 455
intestinal transit, 267
intragastric acidity, 287
intragastric pH, 191
intragastric pH-metry, 47
intravenous ranitidine, 455
irritable bowel syndrome, 175, 87, 543
ischaemia, 29
Isenberg, I. *see* Mcquaid, K. R
Isenberg, J. I. *see* Koss, M. A.
islet cell tumour, 597
itraconazole, 317

Jansen, J. B. M. *see* Janssen, M.
Jansen, J. B. M. J. *see* Witteman, E. M.
Janssen, A. J. H. M. *see* Witteman, E. M.
Janssen, M., Baak, L. C., Jansen, J. B. M., Dijkmans, B. A. C., Vandenbroucke, J. P. & Lamers, C. B. H. W., Effects of indomethacin on intragastric pH and meal-stimulated serum gastrin secretion in rheumatoid arthritis patients, 393
Jarløv, A. E., Munkholm, P., Nordblad Schmidt, P., Langholz, E., Faber Vestergaard, B. & Mølskov Bech, R., Treatment of active ulcerative colitis with immunoglobulin G enemas, 561
Jenkins, A. P. *see* Greenfield, S. M.
Jensen, R. T. *see* Metz, D. C.
Joelsson, B. *see* Johnsson, F.
Johnsson, F., Roth, Y., Damgaard Pederson, N.-E. & Joelsson, B., Cimetidine improves GERD symptoms in patients selected by a validated GERD questionnaire, 81
Jordan, C. C. *see* Anthony, A.

Kamm, M. A. *see* Gattuso, J. M.
Karayiannis, P. *see* Brook, M. G.
Karim, Q. N. *see* Logan, R. P. H.
Kemmer, T. P. *see* Malfertheiner, P.
Kersey, K. *see* Simon, K.
ketanserin, 61
King, P. D. *see* Marshall, J. B.
Klein, P. D. *see* Graham, D. Y.
Kleveland, P. M. *see* Waldum, H. L.
Kogut, D. *see* Robinson M.
Koss, M. A. *see* Mcquaid, K. R.
Koss, M. A., Hogan, D. L., Lane, J., Steinbach, J. H. & Isenberg, J. I., Anti-secretory effects and pharmacokinetics of low dose ranitidine, 417
Kovacs, T. *see* Robinson, M.
Koviack, P. D. *see* Metz, D. C.
Kozarek, R. A., Review article: immunosuppressive therapy for inflammatory bowel disease, 117
Kruis, W. *see* Ziegenhagen, D. J.

Laine, L., Rolling review: upper gastrointestinal bleeding, 207
Lamers, B. H. W. *see* Van De Wal, Y.
Lamers, C. B. H. W. *see* Geus, W. P.
Lamers, C. B. H. W. *see* Janssen, M.
Lane, J. *see* Koss, M. A.
Langholz, E. *see* Jarløv, A. E.
lansoprazole, 191, 629
lavage solution, 523
Law, P. A. *see* Catnach, S. M.
laxatives, 487
Lazzaroni, M., Petrillo, M., Desideri, S., Bianchi Porro, G., efficacy and tolerability of polyethylene glycol electrolyto lavage solution with and without simethicone in the preparation of patients with inflammatory bowel disease for colonoscopy, 655
Ledingham, S. J. *see* Robertson, C. S.
Lee, W. N. Review article: drug-induced hepatotoxicity, 477
Lettis, S. *see* Turnbull, G. M.
leucotrienes, 357
Levitt, M. D. Review article: lack of clinical significance of the interaction between H_2-receptor antagonists and ethanol, 131
Levorato, M. *see* Vaira, D.
Lew, G. M. *see* Graham, D. Y.
Licastro, F. *see* Brignola, C.

Lim, S. G., Sawyer, A. M., Hudson, M., Sercombe, J. & Pounder, R. E., Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity, 319
Lin, C.-H. & Elitsur, Y., A prospective randomized study with mineral oil and oral lavage solution for treatment of faecal impaction in children, 523
lipase, 629
Liu-Jun-Zi-Tang (Rikkhunshi-Fo TJ-43), 457
liver, 131
Ljubicic, W., Bilic, A. & Roic, D., Short report: effect of ranitidine on duodenal ulcer healing in patients with cirrhosis of the liver, 233
Lobo, A. J., Burke, D. A., Sobala, G. M. & Axon, A. T. R., Oral tobramycin in ulcerative colitis: effect on maintenance of remission, 155
Löfberg, R. *see* Danielsson, A.
Löfberg, R., Danielsson, A., Salde, L., Oral budesonide in active Crohn's disease, 611
Logan, R. P. H., Gummett, P. A., Misiewicz, J. J., Karim, Q. N., Walker, M. M. & Baron, J. H., Two-week eradication regimen for metranidazole-resistant *Helicobacter pylori*, 149
Luebke, H. J. *see* Frieling, T.
Luhmann, R. *see* Hartmann, M.
Luk, G. D., Rolling review: gastrointestinal malignancy, 661

McCarthy, C. J., Collins, R., Beattie, S., Hamilton, H. & O'Morain, C., Short report: treatment of *Helicobacter pylori*-associated duodenal ulcer with omeprazole plus antibiotics, 463
McColm, A. A. *see* Stables, R.
McCullough, A. *see* Robinson, M.
McIntyre, A. S., Thompson, D. G., Burnham, W. R. & Walker, E., The effect of beta-adrenoreceptor agonists and antagonists on fructose absorption in man, 267
McLaren, A. *see* Stables, R.
Mcquaid, K. R., Koss, M. A., Crombie, D. L., Hunter, S., Metz, C., Euler, A. E. & Isenberg, I., Gastric acid suppression is greater during intravenous ranitidine infusion bolus injections of famotidine, 537
Main, J. *see* Brook, M. G.
malabsorption, 267
Malaty, H. M. *see* Graham, D. Y.
Malfertheiner, P., Nelson, D. K., Kemmer, T. P., Glasbrenner, B., Schneider, A. & Ditschuneit, H., Exocrine pancreatic secretion in man following one week of M1-muscarinic receptor blockade, 423
Mancini, R. *see* Brignola, C.
Marshall, J. B., Barthel, J. S., King, P. D., Short report: prospective, randomized trial comparing a single dose phosphate regimen with PEG-electrolyte lavage for colonoscopy preparation, 679
Maton, P. N., The management of Zollinger–Ellison syndrome, 467
Maton, P. N. *see* Robinson, M.
May, G. R., Sutherland. L. R. & Shaffer, E. A., Efficacy of bile acid therapy for gallstone dissolution: a meta-analysis of randomized trials, 139
Mazzacca, G. *see* Battaglia, G.
medical treatment, 155
megacolon, 487
Menegatti, M. *see* Vaira, D.
methotrexate, 117
methylprednisolone, 201
methysergide, 61
metoclopramide, 5, 67
metronidazole, 463
metronidazole resistance, 683
metronidazole resistant H. pylori, 149
Metz, C. *see* Mcquaid, K. R.
Metz, D. C., Benya, R. V., Fishbeyn, V. A., Pisegna, J. R., Orbuch, M., Strader, D. B., Norton, J. A. & Jensen, R. T., Prospective study of the need for long-term antisecretory therapy in patients with Zollinger–Ellison syndrome following successful curative gastrinoma resection, 247
Metz, D. C., Strader, D. B., Orbuch, M., Koviack, P. D., Feigenbaum, K. M., Jenson, R. T., Use of omeprazole in Zollinger–Ellison syndrome: a prospective nine-year study of efficacy and safety, 597
Micflikier, A. B. *see* Shoenut, J. P.
Michailidis, D. *see* Arvanitakis, C.
Miglioli, M. *see* Vaira, D.
Mihatov, S. *see* Banic, M.
mineral oil, 523
Misiewicz, J. J. *see* Logan, R. P. H.
Misra, S. C., Dasarathy, S. & Sharma, M. P., Omeprazole versus famotidine in the healing and relapse of duodenal ulcer, 443
Mitchison, H. C. & Bassendine, M. F., Rolling review: autoimmune liver disease, 93
Mocheggiani, E. *see* Brignola, C.
Mølskov Bech, R. *see* Jarløv, A. E.
Morini, M. C. *see* Brignola, C.
Morran, C. *see* Taha, A. S.
mortality, 429
motilin, 61
motility, 327
mucosa, 29
Mulder, C. J. & Tytgat, G. N. J., Review article: topical corticosteroids in inflammatory bowel disease, 125
Mulder, T. P. J. *see* Van De Wal, Y.
Mulé, P. *see* Vaira, D.
Munkholm, P. *see* Jarløv, A. E.

Nakshabendi, I. *see* Taha, A. S.
natural killer cells, 281
Nellans, H. *see* Catnach, S. M.
Nelson, D. K. *see* Malfertheiner, P.
neuroendocrine tumour, 247
neutrophils, 29
Nikopolous, A. *see* Arvanitakis, C.
Nilsson, A. *see* Danielsson, A.
Niwa, Y. *see* Tsukamoto, Y.
nizatidine, 47, 643
non-compliance, 683
non-steroidal anti-inflammatory drugs, 197

Nordblad Schmidt, P. *see* Jarløv, A. E.
Norton, J. A. *see* Metz, D. C.
NSAIDs, 29, 41
Nygard, G. *see* Anthony, A.
Nyman-Pantelidis, M. *see* Danielsson, A.

octreotide, 323
oesophageal motility, 509
oesophageal peristalsis, 75
oesophageal reflux, 509
oesophagitis, 181, 81, 385, 635
Olsson, O. *see* Danielsson, A.
omeprazole, 67, 149, 167, 313, 443, 463, 467, 501, 623
O'Morain, C. *see* Collins, R.
O'Morain, C. *see* McCarthy, C. J.
ondansetron, 5
Orbuch, M. *see* Metz, D. C.
Osman, E., Owen, J. S. & Burroughs, A. K., Review article: S-Adenosyl-L-methionine—a new therapeutic agent in liver disease?, 21
Otten, M. H. *see* Geldof, H.
Owen, J. S. *see* Osman, E.

p-cortisol, 611
pancreatic, 323
Pardoll, P. *see* Robinson, M.
Parente, R. *see* Brignola, C.
Pena, A. S. *see* Van De Wal, Y.
Penston, J. G., Crombie, I. K., Waugh, N. R. & Wormsley, K. G., Trends in morbidity and mortality from peptic ulcer disease: Tayside versus Scotland, 429
Penston, J. G., Dixon, J. S., Boyd, E. J. S. & Wormsley, K. G., A placebo-controlled investigation of duodenal ulcer recurrence after withdrawal of long-term treatment with ranitidine, 259
peptic ulcer, 247, 429, 531, 643
peptic ulcer disease, 589
peptic ulcer therapy, 643
perforation, 429
Petrillo, M. *see* Lazzaroni, M.
pH, 393
pharmacokinetics, 47, 401, 417
Philips, S. F. *see* Hammer, J.
Piasecki, C. *see* Anthony, A.
Pilotto, A. *see* Battaglia, G.
Pisegna, J. R. *see* Metz, D. C.
placebo, 259
platelets, 357
Pohl, C. *see* Ziegenhagen, D. J.
polyethylene glycol, 655
post-prandial activity, 175
post-operative period, 455
Pounder, R. E. *see* Anthony, A.
Pounder, R. E. *see* Lim, S. G.
Poynard, T., French Co-operative Study Group, Relapse rate of patients after healing of oesophagitis—a prospective study of alginate as self-care treatment for 6 months, 385
prednisolone metasulphobenzoate, 125
prednisolone-21-phosphate, 125
Primrose, J. N., Rogers, M. J. & Holmfield, J. H. M., The effects of 300 mg ranitidine at night, twice daily and four times daily on intragastric acidity in normal subjects, 287
Prior, A. & Read, N. W., Reduction in rectal sensitivity and post-prandial motility by granisetron, a 5 HT_3-receptor antagonist, in patients with irritable bowel syndrome, 175
proctitis, 401
prostaglandins, 357
pseudo-obstruction, 487
Punchard, N. A. *see* Greenfield, S. M.

R-Zocopride, 61
radiotelemetry, 287
Ramirez, B. & Richter, J. E., Review article: promotility drugs in the treatment of gastro-oesophageal reflux disease, 5
Ramirez, F. C. *see* Graham, D. Y.
Rampton, D. S. & Collins, C. E., Review article: thromboxanes in inflammatory bowel disease—pathogenic and therapeutic implications, 357
ranitidine, 67, 233, 259, 287, 409, 417, 429, 537, 635, 643
rat, 29
Read, N. W. *see* Prior, A.
receptors, 61
rectal sensitivity, 175, 543
reflux oesophagitis, 409, 501
relapse, 463
relapse risk factors, 385
rheumatoid arthritis, 393
Richardson, P. D. L. *see* Crowe, J. P.
Richter, J. E. *see* Ramirez, B.
Ritchey, T. W. *see* Toskes, P. P.
Roberts, W. *see* Robinson, M.
Robertson, C. *see* Hammer, J.
Robertson, C. S., Evans, D. F., Ledingham, S. J. & Atkinson, M., Cisapride in the treatment of gastro-oesophageal reflux disease, 181
Robinson, M., Decktor, D. L., Maton, P. N., Sabesin, S., Roufail, W., Kogut, D., Roberts, W., McCullough, A., Pardoll, P., Saco, L., Rustgi, V. & Kovacs, T., Omeprazole is superior to ranitidine plus metoclopramide in the short-term treatment of erosive oesophagitis, 67
Rogers, M. J. *see* Primrose, J. N.
Roic, D. *see* Ljubicic, W.
Roth, Y. *see* Johnsson, F.
Rotkvic, I. *see* Banic, M.
Roufail, W. *see* Robinson, M.
Russell, R. I. *see* Taha, A. S.
Rustgi, V. *see* Robinson, M.

Sabesin, S. *see* Robinson, M.
Saco, L. *see* Robinson, M.
Saggioro, A. *see* Corleto, V.
SAMe, 21
Sampliner, E. *see* Fennerty, M. B.
Sandvik, A. K. *see* Waldum, H. L.
Sawyerr, A. M. *see* Lim, S. G.
SC53116, 61

Schembre, D. & Bjorkman, D. J., Review article: endoscopy-related infections, 347
Schneider, A. *see* Malfertheiner, P.
Schwarz, J. A. *see* Dammann, H. G.
scleroderma, 509
Scotland, 429
Scoule, J. C. *see* Vidon, N.
self-care treatment, 385
Sercombe, J. *see* Lim, S. G.
serotonin, 61
serum hormones, 191
Shaffer, E. A. *see* May, G. R.
Sharma, M. P. *see* Misra, S. C.
Shoenut, J. P., Wieler, J. M. & Micflikier, A. B., The extent and pattern of gastro-oesophageal reflux in patients with scleroderma oesophagus: the effect of low-dose omeprazole, 509
simethicone, 655
Simon, K., Zuk, L., Pinchbeck, B., Wasarab-Rolland, D., Kersey, K., Effect of intravenous infusion of ranitidine on intragastric acidity in fasting subjects: comparison with bolus or Gastrojet (pH-stat-adjusted), 649
small intestine, 29, 327
Smith, S. J. *see* Geus, W. P.
smoking, 41, 683
smooth muscle, 29
Sobala, G. M. *see* Lobo, A. J.
somastotatin, 323
Sontag, S. J., Rolling review: gastro oesophageal reflux disease, 293
spike potentials, 327
Stables, R., Campbell, C. J., Clayton, N. M., Clitherow, J. W., Grinham, R., McColm, A. A., McLaren, A. & Trevethick, M. A., Gastric anti-secretory, mucosal protective, anti-pepsin and anti-*Helicobacter* properties of ranitidine bismuth citrate, 327
Steele, R. J. *see* Hudson, N.
Steinbach, J. H. *see* Koss, M. A.
steroid withdrawal, 331
stomach, 41, 131, 247, 597
Strader, D. B. *see* Metz, D. C.
stress ulceration, 455
Strong, P. *see* Anthony, A.
Sturrock, R. D. *see* Taha, A. S.
substance p, 61
sucralfate, 581
Suhr, O. *see* Danielsson, A.
sulcrafate gel, 531
sulcrafate suspension, 531
sulphasalazine, 369
surgery, 487
Sutherland, L. R. *see* May, G. R.
Sutton, R. *see* Gore, S.
Swannell, A. J. *see* Hudson, N.
Syversen, U. *see* Waldum, H. L.

Taha, A. S., Angerson, W., Nakshabendi, I., Beekman, H., Morran, C., Sturrock, R. D. & Russell, R. I., Gastric and duodenal mucosal blood flow in patients receiving non-steroidal anti-inflammatory drugs—influence of age, smoking, ulceration and *Helicobacter pylori*, 41
Talley, N. J. *see* Hammer, J.
Tatsuta, M. & Iishi, H., Effect of treatment with Liu-Jun-Zi-Tan (TJ-43) on gastric emptying and gastrointestinal symptoms in dyspeptic patients, 459
Taylor, M. D. *see* Crowe, J. P.
Tayside, 429
Teare, J. P. *see* Greenfield, S. M.
tetracycline, 111, 463
Theoharidis, A. *see* Arvanitakis, C.
therapy, 201, 139, 567
Thomas, H. C. *see* Brook, M. G.
Thomforde, G. M. *see* Valdovinos, M. A.
Thompson, D. G. *see* McIntyre, A. S.
Thompson, R. P. H. *see* Greenfield, S. M.
thromboxanes, 357
thymulin, 275
tixocortol pivalate, 125
tobramycin, 155
Toskes, P. P., Connery, K. L. & Ritchey, T. W., Calcium polycarbophil compared with placebo in irritable bowel syndrome, 87
Toukantonis, A. *see* Arvanitakis, C.
Tovey, F. I., Alexander-Williams, J., Letter to the Editor, 689
treatment/therapy, 117, 611
Trevethick, M. A. *see* Anthony, A.
Trevethick, M. A. *see* Stables, R.
trimebutine, 327
triple therapy, 111
Troskot, B. *see* Banic, M.
Tsuchida, T. *see* Tsukamoto, Y.
Tsukamoto, Y., Tsuchida, T., Goto, H., Hase, S., Arisawa, T. & Niwa, Y., Effect of sulcrafate on angiogenesis in granulation tissue of acetic acid-induced gastric ulcers in rats, 581
Tulassay, Z., Flautner, L., Vadasz, A. & Fehervari, I., Short report: octreotide in the treatment of external pancreatic fistulas, 325
Turnbull, G. M., Lettis, S. & Hawkey, C. J., Ranitidine bismuth citrate prevents aspirin-induced gastric mucosal injury, 515
Tytgat, G. N. J. *see* Mulder, C. J.
Tytgat, G. N. J. *see* Witteman, E. M.

ulcer treatment, 259
ulceration, 29
ulcerative, 357
ulcerative colitis, 125, 155, 159, 117, 567, 561
ulcerative colitis distal, 401
ulcers, 41, 467
ursodeoxycholic acid, 139

Vadasz, A. *see* Tulassay, Z.
Vagios, I. see Arvanitakis, C.
Vaira, D., Corbelli, C., Brunetti, G., Menegatti, M., Levorato, M., Mulé, P., Colombo, P., Miglioli, M. & Barbara, L.,

Gastric retention of sucralfate gel and suspension in upper gastrointestinal diseases, 531
Valdovinos, M. A., Thomforde, G. M. & Camilleri, M., Effect of putative carcinoid mediators on gastric and small bowel transit in rats and the role of 5-HT receptors, 61
Van De Wal, Y., Van Der Sluys Veer, A., Verspaget, H. W., Mulder, T. P. J., Griffioen, G., Van Tol, E. A. F., Pena, A. S. & Lamers, B. H. W., Effect of zinc therapy on natural killer cell activity in inflammatory bowel disease, 281
Van Der Sluys Veer, A. *see* Van De Wal, Y.
Van Tol, E. A. F. *see* Van De Wal, Y.
Vandenbroucke, J. P. *see* Janssen, M.
Verspaget, H. W. *see* Van De Wal, Y.
Vidon, N., Dutreuil, C., Scoule, J. C., Delchier, J. C., Does potent inhibition of gastric acid secretion influence post-prandial digestive function?, 629
Vigneri, S. *see* Battaglia, G.
villi, 29
Vinks, A. A. T. M. *see* Geus, W. P.
Von Zur Muhlen, A. *see* Dammann, H. G.

Wakefield, A. J. *see* Anthony, A.
Waldum, H. L., Brenna, E., Kleveland, P. M., Sandvik, A. K., Syversen, U., Review article: the use of gastric acid-inhibitory drugs-physiological and pathophysiological considerations, 589
Walker, E. *see* McIntyre, A. S.
Walker, M. M. *see* Logan, R. P. H.
Walt, R. P., Reply to the letter to the Editors, 115
Wasarab-Rolland, D. *see* Simon, K.
Waugh, N. R. *see* Penston, J. G.
Westra, P. *see* Geus, W. P.
Wieler, J. M. *see* Shoenut, J. P.
Wienbeck, M. *see* Frieling, T.
Wilkinson, M. J. *see* Hudson, N.
Willen, R. *see* Danielsson, A.
Witteman, E. M., Hopman, W. P. F., Becx, M. C. J. M., De Koning, R. W., Tytgat, G. N. J., Janssen, A. J. H. M., Jansen, J. B. M. J., Short report: smoking habits and the acquisition of metronidazole resistance in patients with *Helicobacter pylori*-related gastritis, 683
Wormsley, K. G. *see* Penston, J. G.
Wurst, W. *see* Hartmann, M.

Xia, H. X. *see* Collins, R.

Yap, I. *see* Brook, M. G.

Zehnter, E. *see* Ziegenhagen, D. J.
Ziegenhagen, D. J., Heitz, W., Kruis, W., Pohl, C., Zehnter, E., Cisapride increased gallbladder volume in gallstone patients before and after extracorporeal shock wave lithotripsy, 617
zinc, 275, 281
Zollinger-Ellison syndrome, 167
Zuk, L. *see* Simon, K.